![Karin Ann Thacker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Karin Ann Thacker
Consigliere Generale presso SENTI BIOSCIENCES, INC.
Profilo
Karin Ann Thacker is currently the Vice President-Quality & Regulatory Affairs at Senti Biosciences, Inc. She previously worked as the Senior Director & Head-Regulatory Development at Puma Biotechnology, Inc. from 2015 to 2016.
From 2020 to 2022, she served as the VP-Regulatory Affairs & Quality Assurance at Harpoon Therapeutics, Inc. Prior to that, she was the Vice President-Global Regulatory Affairs at Gritstone bio, Inc. from 2016 to 2020.
Ms. Thacker completed her undergraduate and graduate degrees at the University of Manitoba.
Posizioni attive di Karin Ann Thacker
Società | Posizione | Inizio |
---|---|---|
SENTI BIOSCIENCES, INC. | Consigliere Generale | - |
Precedenti posizioni note di Karin Ann Thacker
Società | Posizione | Fine |
---|---|---|
HARPOON THERAPEUTICS, INC. | Consigliere Generale | 01/08/2022 |
GRITSTONE BIO, INC. | Consigliere Generale | 01/08/2020 |
PUMA BIOTECHNOLOGY, INC. | Corporate Officer/Principal | 01/05/2016 |
Formazione di Karin Ann Thacker
University of Manitoba | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
GRITSTONE BIO, INC. | Health Technology |
PUMA BIOTECHNOLOGY, INC. | Health Technology |
SENTI BIOSCIENCES, INC. | Health Technology |
Aziende private | 1 |
---|---|
Harpoon Therapeutics, Inc.
![]() Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Karin Ann Thacker